Alexion Says UK Unit Informed AGNSS Recommendation for Soliris Won't Be Followed
Posted on January 23, 2013 at 14:46 PM EST
Alexion Pharma UK, a subsidiary of Alexion Pharmaceuticals, Inc. (NASDA: ALXN), has been informed by the National Specialised Commissioning Team (NSCT) that the Ministers of Health have decided to not follow a positive recommendation by the Advisory Group for National Specialised Services (AGNSS) when assessing Soliris® (eculizumab) as a treatment